

## Sphingosine 1 Phosphate Receptor (S1pr) Modulator Drugs Market Analysis: Key Trends, Share, Growth Drivers

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

LONDON, GREATER LONDON, UNITED KINGDOM, March 28, 2025 /EINPresswire.com/ -- What does the <u>S1PR Modulator Drugs Market forecast</u> look like?



The sphingosine 1 phosphate receptor S1PR modulator drugs market size has grown strongly in recent years. It will grow from \$2.44 billion in 2024 to \$2.60 billion in 2025 at a compound annual growth rate CAGR of 6.3%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increased investment in autoimmune drug development, expansion of indications, growing awareness of autoimmune disease management, and rising healthcare expenditure.

What are the key drivers of the S1PR Modulator drugs market?

Going forward, the S1PR modulator drugs market size is expected to see significant growth. It will grow to \$3.28 billion in 2029 at a compound annual growth rate CAGR of 6.0%. The forecast period growth can be attributed to growing demand for oral therapies over injectables, increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, growth in awareness and diagnosis of conditions like multiple sclerosis, and a rising geriatric population prone to autoimmune diseases.

The rising prevalence of autoimmune diseases is a major factor propelling the S1PR modulator drugs market growth. Autoimmune diseases are conditions where the immune system mistakenly attacks the body's own healthy cells, causing inflammation and damage. Genetic factors, environmental triggers, lifestyle changes, and improved diagnostics are driving the increase in autoimmune diseases. Sphingosine 1-Phosphate Receptor S1PR modulator drugs, used in autoimmune diseases, regulate immune cell migration, reducing inflammation in conditions like multiple sclerosis and ulcerative colitis.

Get Your Free Sample Market Report:

## https://www.thebusinessresearchcompany.com/sample.aspx?id=21288&type=smp

Which companies are leading the S1PR Modulator Drugs Market? Major companies operating in the S1PR modulator drugs market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, Novartis International AG, Biogen Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Actelion Pharmaceuticals Ltd., KYORIN Pharmaceutical Co. Ltd., Vanda Pharmaceuticals Inc., Celgene Corporation, Ventyx Biosciences Inc., Idorsia Pharmaceuticals Ltd., Cayman Chemical Company, Juvisé Pharmaceuticals, Priothera Limited, Arena Pharmaceuticals.

What are the emerging trends in the S1PR Modulator Drugs Market?

In the market, companies are focusing on innovative therapies, such as oral therapy. This approach enhances patient compliance, improves drug efficacy, and extends the therapeutic potential of S1PR modulator drugs for treating autoimmune diseases and related conditions. For example, in March 2022, Pfizer announced positive phase 3 trial results for etrasimod in ulcerative colitis patients. The drug met its primary and key secondary endpoints showing significant improvements in remission, endoscopic outcomes, and symptom relief.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/sphingosine-1-phosphate-receptor-s1prmodulator-drugs-global-market-report

How is the <u>S1PR Modulator Drugs Market segmented?</u>

- 1 By Type: Fingolimod, Ozanimod
- 2 By Route Of Administration: Oral, Injectable, Topical
- 3 By Application: Multiple Sclerosis, Cardiovascular Diseases, Transplant Rejection
- 4 By End User: Hospital, Rehabilitation Centres, Retail Pharmacies
- Subsegments:
- 1 By Fingolimod: Branded Formulations, Generic Formulations
- 2 By Ozanimod: Oral Capsules, Other Formulations

What is the regional outlook for the S1PR Modulator Drugs Market? In 2024, Asia-Pacific was the largest region in the S1PR modulator drugs market. The regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By <u>The Business Research Company</u>:

Hyperphosphatemia Treatment Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-</u> <u>market-report</u>

Phosphate Fertilizer Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/phosphate-fertilizer-global-marketreport

Lithium Iron Phosphate Battery Global Market Report 2025 <u>https://www.thebusinessresearchcompany.com/report/lithium-iron-phosphate-battery-global-market-report</u>

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at: The Business Research Company: <u>https://www.thebusinessresearchcompany.com/</u> Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on: LinkedIn: <u>https://in.linkedin.com/company/the-business-research-company</u> YouTube: <u>https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ</u> Global Market Model: <u>https://www.thebusinessresearchcompany.com/global-market-model</u>

Oliver Guirdham The Business Research Company 20 7193 0708 info@tbrc.info

This press release can be viewed online at: https://www.einpresswire.com/article/797985787

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire<sup>™</sup>, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.